Healthcare IPO: Gaudium IVF and Women Health Limited is preparing to launch its public issue later this month, marking its entry into the capital markets. The IPO will open for subscription on February 20, 2026, and close on February 24, 2026. The shares are scheduled to list on February 27, subject to final approvals.
The company has set a price band of ₹75 to ₹79 per share. Investors will have to apply for a minimum lot of 788 shares, which requires an investment of a little over ₹62,000 at the upper end of the price band. The total size of the issue stands at ₹165 crore.
| Particulars | Details |
|---|---|
| Price Range | ₹75 – ₹79 per share |
| Lot Size | 788 shares |
| Investment (1 Lot) | ₹62,252 (at ₹79) |
| Issue Size | ₹165 Crore |
Business Overview
Gaudium IVF operates in the fertility treatment space, focusing on assisted reproductive technologies. Its service portfolio includes IVF procedures, ICSI treatments, and IUI services. The company has gradually expanded its network across multiple states and currently runs more than 30 centres under a structured hub-and-spoke model.
The business was founded by fertility specialist Dr. Manika Khanna and has positioned itself as a specialised healthcare provider in the women’s health segment. Over the years, the company has expanded beyond Delhi into several regional markets, aiming to build a broader footprint in India’s growing fertility services industry.
How the Funds Will Be Used
According to the offer documents, a large portion of the IPO proceeds will be used to set up new IVF centres. The company also plans to use part of the funds to reduce existing debt, while the remaining amount will go towards general corporate requirements.
Expansion into new cities and strengthening infrastructure appears to be a key focus area going forward.
IPO Schedule
| Event | Date |
|---|---|
| Issue Opens | 20 Feb 2026 |
| Issue Closes | 24 Feb 2026 |
| Allotment Finalisation | 25 Feb 2026 |
| Refund Initiation | 26 Feb 2026 |
| Share Credit to Demat | 26 Feb 2026 |
| Listing Date | 27 Feb 2026 |
Note: Dates are tentative and subject to change.
Sector Context
India’s fertility services industry has been expanding due to increasing awareness, delayed parenthood trends, and better access to medical technology. However, healthcare businesses also face regulatory, operational, and staffing challenges.
Like many healthcare providers, Gaudium’s performance depends heavily on medical expertise, skilled embryologists, and patient trust. Any disruption in these areas can impact operations.
What to Watch
Investors tracking the IPO may pay attention to the company’s financial track record, debt levels, expansion costs, and sustainability of cash flows. The fertility treatment segment offers long-term growth potential, but it is also competitive and service-intensive.
Disclaimer: BBK24.COM provides news and information on markets, economy, business, and personal finance for informational purposes only. We do not provide financial advice, and any action you take based on our content is at your own risk. Please consult a licensed professional before making investment decisions.